Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 7/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GLB1 | P16278 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14968375 | 1.00 | TRPA1 (0.40) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL1867589 | 0.85 | — | — | |
| SCHEMBL12936106 | 0.85 | — | — | |
| SCHEMBL13649859 | 0.85 | — | — | |
| SCHEMBL6884095 | 0.85 | — | — | |
| SCHEMBL6822222 | 0.85 | — | — | |
| SCHEMBL6932575 | 0.84 | FUCA1 (0.40) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL16265023 | 0.82 | TRPA1 (0.50) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL5868538 | 0.79 | TRPA1 (0.40) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL4951181 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165972-A1 | CANCER THERAPY WITH MICROBUBBLES | Sonotarg Limited (GB) | 2023-06-01 | — | — | US | disclosed |
| WO-2023080785-A1 | PATATIN INHIBITION | Coöperatie Koninklijke Avebe U.A. (NL) | 2023-05-11 | — | — | WO | disclosed |
| EP-1754702-B1 | EPIGALLOCATECHIN DIMERS OR TRIMERS HAVING LIPASE INHIBITORY ACTIVITY AND/OR ANTIOXIDATIVE ACTIVITY | SUNTORY HOLDINGS LTD (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-5545631-A | GAMMA-AMINOBUTYRIC ACID ANTAGONIST; TREATS PETIT-MAL TYPE EPILEPSIES | CIBA-GEIGY CORPORATION (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| US-5407922-A | GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1995-04-18 | — | — | US | disclosed |
| US-5229379-A | Gamma-aminobutyric acid antagonists | CIBA-GEIGY CORPORATION (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165972-A1 | CANCER THERAPY WITH MICROBUBBLES | ANXA5, FOLR2, PAICS | TRPA1 3865/4885TRPM8 4645/4885CA1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.